Short Reads

Recent European Commission merger decisions signal an increased focus on innovation

Recent European Commission merger decisions signal an increased focus on innovation

03.07.2017 EU law

On 27 March 2017, the European Commission approved a merger between chemical companies Dow and DuPont subject to major remedies, including the divestment of DuPont's global R&D organisation. In this case, the Commission's review extended to the merger's potential impact on innovation "at the overall industry level". 

The Commission considered that innovation is a key competitive parameter in the pesticides industry. According to the Commission, post-merger, only three integrated players could effectively compete with Dow/DuPont at a global level throughout the entire (R&D) value chain (from discovering new active ingredients, to the manufacture and sale of final products). The Commission relied on evidence showing that the parties intended to cut back on R&D expenditure, and that the merged entity would have less incentives to innovate than Dow and DuPont would have separately. As a result, the Commission found that the merger would have significantly reduced "innovation competition" for pesticides, and called for the divestment of the vast majority of DuPont's global R&D organisation.

The importance of "innovation" as an assessment parameter under EU merger control law is not particularly new and is reflected in the Commission's horizontal merger guidelines (the Guidelines). The Guidelines, for example, recognise that a merger between two important innovators developing competing "pipeline" products (in a specific product market) may, under certain conditions, impede competition.

The assessment of such "pipeline overlaps" has played a role in numerous pharmaceutical merger decisions over the years. Traditionally, the Commission focused its review on pipeline products that have entered late phase (phase III) clinical trials. Such products have a higher likelihood of entering the market within a reasonably foreseeable timeframe. In recent years, however, the Commission has extended its review to products in the early stages of development, many of which may never be marketed. In Novartis/GSK Oncology, for example, the Commission analysed the merger's potential impact on the parties' overall clinical research programmes for ovarian and skin cancer treatments, including very early phase (phase I) pipeline products. More recently, on 9 June 2017, the Commission cleared a merger between J&J and Actelion, subject to commitments ensuring that the parties' phase II pipeline products would not be delayed or discontinued.

These developments show that – at least in innovation intensive industries – the Commission will continue to review the merging parties' full R&D portfolios in detail. This may require significant additional preparatory work (e.g. in terms of document collection and preparing economic analyses) before mergers are filed.

This article was published in the Competition Law Newsletter of July 2017. Other articles in this newsletter:

  1. Google gets a record EUR 2.42 billion antitrust fine for its shopping service
  2. ACM fines Dutch rail operator (NS) for an alleged abuse of dominance
  3. New Belgian Act on damage claims for competition law infringements


Related news

16.03.2018 BE law
(Micro)plastics: EU-restrictie op komst?

Articles - Lees hier meer over de groeiende aandacht voor microplastics, die meer en meer in producten en levensmiddelen opduiken. De Europese instellingen hebben de microplastics in het vizier vanwege hun mogelijke impact op het marien milieu en de menselijke gezondheid. Ze denken na over beperkingen op microplastics. Volgen ook in België  bindende maatregelen?

Read more

01.03.2018 EU law
ACM publishes key priorities for 2018 and 2019

Short Reads - On 13 February 2018, the Dutch Authority for Consumers and Markets (ACM) highlighted the key priorities it will pursue in 2018 and 2019. It will focus on the digital economy, making the energy market greener, prices of prescription drugs and competition in the port sector. Interested parties were invited to share their comments on the priorities and multiple statements online.

Read more

14.03.2018 EU law
The Court of Justice of the European Union Rules that Intra-EU Investment Arbitration is Incompatible with EU Law: Reflections and Consequences for the Energy Charter Treaty

Articles - On the 6th of March 2018, the Court of Justice of the European Union (CJEU) held in a case between the Slovak Republic and Achmea (Case C-284/16, ECLI:EU:C:2018:158) that investment arbitration on the basis of the Netherlands-Slovakia Bilateral Investment Treaty (BIT) is incompatible with EU law, in particular Arts. 267 and 344 of the Treaty on the Functioning of the European Union (TFEU). 

Read more

27.02.2018 BE law
Kleinhandelsbeleid getoetst aan Dienstenrichtlijn

Articles - Het Hof van Justitie heeft in een recent arrest de Dienstenrichtlijn van toepassing verklaard op "detailhandel". Dit arrest heeft belangrijke gevolgen voor het lokale kleinhandelsbeleid. Zo zal een gemeente of een provincie die de toegang tot of de uitoefening van een dienstenactiviteit beperkt, afdoende moeten motiveren waarom die belemmering verstaanbaar is met de Dienstenrichtlijn. Het bestuur moet dan ook waakzamer dan ooit zijn wil het een wettig kleinhandelsbeleid voeren. 

Read more

Our website uses cookies: third party analytics cookies to best adapt our website to your needs & cookies to enable social media functionalities. For more information on the use of cookies, please check our Privacy and Cookie Policy. Please note that you can change your cookie opt-ins at any time via your browser settings.

Privacy – en cookieverklaring